Intelligence · Patents
Patents expiring in 2040
Annual patent cliff calendar for 2040 — US pharmaceutical patents by expiration date.
- Patents
- 1,866
Quick answer
1,866 indexed pharmaceutical patents have expiration dates in 2040. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 2020339710
GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF
granted -
US 10822422
Antibodies against TL1a and uses thereof
granted -
US 10821074
Sublingual and buccal film compositions
granted -
US 10822299
Compounds and methods for hematopoietic regeneration
granted -
US 10822608
Oligonucleotide analogues targeting human LMNA
granted -
US 10822599
Compositions for linking DNA-binding domains and cleavage domains
granted -
US 10822588
Agents and methods to elicit anti-tumor immune response
granted -
US 10822426
Humanized anti-CD73 antibodies
granted -
US 10822429
Etanercept formulations exhibiting marked reduction in sub-visible particles
granted -
US 10822585
Compositions and methods for treating retinal diseases
granted -
US 10822414
Anti-PD-1 antibodies, compositions comprising anti-PD-1 antibodies and methods of using anti-PD-1 antibodies
granted -
US 10822378
Mutated structural protein of a parvovirus
granted -
US 10822369
Compounds and methods for the modulation of proteins
granted -
US 10822340
Substituted imidazolopyrazine compounds and methods of using same
granted -
US 10822337
TGF-β inhibitorC
granted -
US 10822301
3-carbon substituted 4-aminocyclopent-1-ene-1-carboxylic acid compounds as inhibitors of gamma-aminobutyric acid (GABA) aminotransferase
granted -
US 10821190
HIV peptide vaults and methods of making and using thereof
granted -
US 10821186
Lipids and compositions for the delivery of therapeutics
granted -
US 10821163
Process for the production of a DNA vaccine for cancer immunotherapy
granted -
US 10821149
Composition and the use thereof
granted -
US 10821182
Pharmaceutical compositions comprising meloxicam
granted -
US 10821181
Pharmaceutical compositions comprising meloxicam
granted -
US 10822421
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
granted -
US 10821134
BK virus specific T cells
granted -
US 10822353
Dithio ETP derivatives
granted -
US 10821117
Estrogen therapy for brain gray matter atrophy and associated disability
granted -
US 10821099
Use of tradipitant in motion sickness
granted -
US 10821078
Nanostructure enhanced targeting (NSET) of inflammatory cells
granted -
US 10821178
Methods of treating biofilm infections comprising administering inhibitors of myeloid-derived suppressor cells
granted -
US 10821103
Substituted pyridinone-containing trycyclic compounds, and methods using same
granted -
US 10822387
Binding-triggered transcriptional switches and methods of use thereof
granted -
US 10822427
Anti-CSPG4 fusions with interferon for the treatment of malignancy
granted -
US 10822316
3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
granted -
US 10820615
Powder formulation having a function of enhancing immunity and method for preparing the same
granted -
US 10821092
Viscous topical ocular formulations
granted -
US 10821146
Powder formulation having a function of enhancing immunity and method for preparing the same
granted -
US 2020345623
METHODS OF SCAR PREVENTION AND/OR TREATMENT
granted -
US 10828280
Glucocorticoid receptor modulators to treat pancreatic cancer
granted -
US 10829465
Highly purified pharmaceutical grade tasimelteon
granted -
US 10829438
Neprilysin inhibitors
granted -
US 10828364
Method for reducing a myeloid derived suppressor cell population with cationic lipid vaccine compositions
granted -
US 10833330
Sulfur composites and polymeric materials from elemental sulfur
granted -
US 10829485
ATF6 inhibitors and uses thereof
granted -
US 10829768
Chimeric antigen receptors targeting B-cell maturation antigen
granted -
US 10828265
Formulations of propranolol and analogs as an amorphous melt or ionic liquid for transdermal drug delivery
granted -
US 10828250
Topical formulation
granted -
US 10829795
Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates
granted -
US 10829752
Bacterial toxins and uses thereof as Ras specific proteases for treating cell proliferation diseases and disorders
granted
Frequently asked questions
How many pharma patents expire in 2040?
1,866 published patents in our USPTO index have expiration dates falling in calendar year 2040.